Prostate cancer gene therapy clinical trials.
Despite recent advances in early detection and treatment, prostate cancer is still the second leading cause of cancer death in men in the United States, and approximately 27,000 men will die from it this year. Better treatments are needed for aggressive forms of localized disease and hormone-refractory metastatic disease. Recently, several gene therapy strategies have generated provocative results in early-stage clinical trials, raising the possibility that gene therapy may have the potential to affect both localized and metastatic disease. Much work lies ahead. Nevertheless, for the time being, these studies provide hope that gene therapy may someday earn a place in the management of prostate cancer.
Freytag
Svend O
SO
Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan 48202, USA. sfreyta1@hfhs.org
Stricker
Hans
H
Movsas
Benjamin
B
Kim
Jae Ho
JH
D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome